Riskpilot← Back to searchSign inGet full accessACESION PHARMA ApS
APSActiveCVR 34083738Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 201116 employees
Revenue 2024
—
EBITDA margin
—
-8% vs 2023
Equity ratio
77.2%
Financial strength
Net profit 2024
DKK -43M
0% vs 2023
| Revenue | — | — |
| EBITDA | DKK -57,2M | -8% |
| Net profit | DKK -43M | +0% |
| Total assets | DKK 116,1M | -30% |
| Equity | DKK 89,6M | -31% |
| Employees | 16 | — |
Legal name
ACESION PHARMA ApS
CVR number
34083738
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15. december 2011
Share capital
DKK 189.063.037
Employees
16 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af tre bestyrelsesmedlemmer eller af en direktør og bestyrelsesformanden i forening.
Company purpose
Selskabets formål er at udvikle lægemidler til medicinsk behandling af atrieflimmer.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.314 | -4.833 | -4.722 | -8.496 | -14.394 | -17.451 | -18.647 | -35.794 | 0 | 0 | — | — | — |
| Staff expenses | -1.228 | -2.789 | -3.489 | -3.857 | -8.214 | -11.748 | -11.791 | -10.768 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2.542 | -7.622 | -8.212 | -12.354 | -22.608 | -29.199 | -30.438 | -46.562 | -36.311 | -37.897 | -56.635 | -53.020 | -57.245 |
| Depreciation & amort. | -0 | -108 | -184 | -211 | -213 | -215 | -104 | -29 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.542 | -7.730 | -8.396 | -12.565 | -22.821 | -29.414 | -30.542 | -46.591 | -36.311 | -37.897 | -56.635 | -53.020 | -57.245 |
| Net financials | 11 | -0 | 4 | -30 | 2 | -59 | -47 | -132 | -617 | 4.844 | -3.530 | -2.805 | 1.311 |
| Profit before tax | -2.531 | -7.730 | -8.392 | -12.595 | -22.819 | -29.472 | -30.588 | -46.723 | -36.928 | -33.053 | -60.165 | -55.824 | -55.934 |
| Tax | -462 | -1.223 | -1.937 | -2.790 | -4.556 | -5.500 | -5.500 | -5.500 | -5.500 | -7.896 | -13.385 | -12.975 | -12.901 |
| Net profit | -2.069 | -6.507 | -6.455 | -9.804 | -18.262 | -23.972 | -25.088 | -41.223 | -31.428 | -25.157 | -46.780 | -42.849 | -43.033 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.629 | 9.056 | 18.887 | 17.288 | 39.786 | 22.817 | 29.379 | 31.475 | 64.533 | 33.954 | 53.191 | 165.939 | 116.146 |
| Equity | 1.951 | -556 | 3.832 | 1.536 | 14.054 | -9.918 | -6.496 | 524 | -20.048 | 10.344 | 22.983 | 130.799 | 89.642 |
| Long-term debt | 0 | 8.804 | 13.639 | 10.966 | 19.863 | 26.394 | 30.593 | 226 | 43.593 | 17.692 | 18.489 | 14.039 | 7.762 |
| Short-term debt | 678 | 781 | 1.417 | 4.787 | 5.869 | 6.341 | 5.282 | 30.726 | 40.988 | 5.919 | 11.719 | 21.101 | 18.742 |
| Total debt | 678 | 9.585 | 15.055 | 15.752 | 25.732 | 32.735 | 35.875 | 30.952 | 84.581 | 23.611 | 30.208 | 35.140 | 26.504 |
EBITDA margin
-5724500000.0%
This company
15.8%
Market median
-36231012758% vs market
20122024
Equity ratio
77.2%
This company
38.2%
Market median
+102% vs market
20122024
Return on equity
-48.0%
This company
18.4%
Market median
-361% vs market
20122024
Net profit margin
-4303300000.0%
This company
8.1%
Market median
-53127160594% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2011-12-15 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
US Founder | Founder | 2011 | — | — |
FG Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
JD Management | Management | 2017 | — | — |
TV Management | Management | 2018 | — | — |
AG Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
MG Founder | Founder | 2011 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 33.3% | 33.3% | 2025 |
| Individual | 20.0% | 20.0% | 2025 | |
| Individual | 15.0% | 15.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2022 | |
Uddannelses- og Forskningsstyrelsen | Company | 5.0% | 5.0% | 2016 |
| Individual | 5.0% | 5.0% | 2021 | |
| Individual | 5.0% | 5.0% | 2019 | |
| Individual | 5.0% | 5.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
ACESION PHARMA ApS Board members of ACESION PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrik Svane Sørensen | Founder | 0 companies |
| Frans Gustaf Wuite | Chief Executive Officer | 0 companies |
| Jakob Dynnes Hansen | Management | 0 companies |
| Torgeir Vaage | Management | 0 companies |
| Anders Gaarsdal Holst | Chief Executive Officer | 0 companies |
| Morten Grunnet | Founder | 0 companies |
| Jørgen Søberg Petersen | Chairman | 0 companies |
| Bobby G Soni | Board of Directors | 0 companies |
| Ann Mills-Duggan | Board of Directors | 0 companies |
| Karen Juo-Lai Chu | Board of Directors | 0 companies |
| Morten Døssing | Board of Directors | 0 companies |
| Duan Xiang | Board of Directors | 0 companies |
| Paul David Goldenheim | Board of Directors | 0 companies |
| Ingelise Saunders | Chairman | 0 companies |
| Stephan Christgau | Board of Directors | 0 companies |
| Frank Knudsen | Board of Directors | 0 companies |
| Georgios Trichas | Board of Directors | 0 companies |
| Carsten Schou | Board of Directors | 0 companies |
| Lars Gredsted | Board of Directors | 0 companies |
| Timothy Michael Shannon | Board of Directors | 0 companies |
| Benjamin Bruno Thorner | Board of Directors | 0 companies |
| Nik Economopoulos | Board of Directors | 0 companies |